Pseudomonas aeruginosa Recombinant L-asparaginase: PEGylation with Low Molecular Weight Polyethylene Glycol, Molecular Dynamics Simulation, In vitro and In vivo Serum half-life and Biochemical Characterization
- PMID: 38994625
- DOI: 10.2174/0113892010309260240624072408
Pseudomonas aeruginosa Recombinant L-asparaginase: PEGylation with Low Molecular Weight Polyethylene Glycol, Molecular Dynamics Simulation, In vitro and In vivo Serum half-life and Biochemical Characterization
Abstract
Background: Microbial L-asparaginase (L-ASNase, EC 3.5.1.1) is a pivotal biopharmaceutical drug-protein that catalyzes the hydrolysis of the non-essential amino acid L-asparagine (L-Asn) into L-aspartic acid (L-Asp) and ammonia , resulting in deplenishing the cellular L-Asn pool, which leads to the ultimate death of the L-asparagine synthetase (L-ASNS) deficient cancerous cells.
Objective: This study aimed to investigate the impact of conjugating low molecular weight polyethylene glycol to recombinant P. aeruginosa L-ASNase by examining the pharmacokinetic properties, affinity towards the substrate, and enzyme stability prior to and following the reaction.
Methods: The recombinant P. aeruginosa L-ASNase was affinity purified and then PEGylated by attaching polyethylene glycol (MW= 330 Da) site-specifically to the protein's N-terminus end. After which, the PEGylated L-ASNase was examined by SDS-PAGE (15%), FTIR, and UV/Vis spectrophotometry and subsequently biochemically characterized.
Results: The Km and Vmax values of free P. aeruginosa rL-ASNase were determined to be 0.318 ±1.76 mM and 2915 μmol min-1 and following the PEGylation, they were found to be 0.396 ±1.736 mM and 3193 μmol min-1, respectively. Polyethylene glycol (330 Da) has markedly enhanced LASNase thermostability at 37, 45, 50, and 55°C, as opposed to the free enzyme, which retained 19.5% after 1 h of incubation at 37°C. The PEGylated L-ASNase was found to be stable upon incubation with human serum for 28 h, in contrast to the sharp decline in the residual bioactivity of the free rL-ASNase after 4 h incubation. Accordingly, an in vivo study was used for validation, and it demonstrated that PEGylated rL-ASNase exhibited longer bioactivity for 24 h, while the free form's activity vanished entirely from the rats' blood sera after 8 h. Molecular dynamics simulation indicated that PEG (330 Da) has affected the hydrodynamic volume of L-ASNase and increased its structural stability. Docking analysis has explored the position of PEG with respect to binding sites and predicted a similar binding affinity to that of the free enzyme.
Conclusion: For the first time, recombinant L-ASNase was modified by covalently attaching PEG (330 Da). The resultant novel proposed PEGylated rL-ASNase with remarkably increased stability and prolonged in vivo half-life duration, could be considered an alternative to mitigate the high molecular weight of PEGylation's drawbacks.
Keywords: L-asparaginase; PEGylation; bio-better.; immunogenicity; molecular docking; molecular dynamic simulation; pharmacokinetics.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Expression and Functional Characterization of Pseudomonas aeruginosa Recombinant L.Asparaginase.Protein J. 2018 Oct;37(5):461-471. doi: 10.1007/s10930-018-9789-3. Protein J. 2018. PMID: 30097831
-
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.Cancer Chemother Pharmacol. 2017 Jun;79(6):1267-1271. doi: 10.1007/s00280-017-3307-8. Epub 2017 Apr 19. Cancer Chemother Pharmacol. 2017. PMID: 28424964
-
Polyethylene Glycol Acts as a Mechanistic Stabilizer of L-asparaginase: A Computational Probing.Med Chem. 2019;15(6):705-714. doi: 10.2174/1573406415666190206232816. Med Chem. 2019. PMID: 30727907
-
Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.Int J Nanomedicine. 2006;1(3):241-54. Int J Nanomedicine. 2006. PMID: 17717965 Free PMC article. Review.
-
L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.Leuk Lymphoma. 2014 Feb;55(2):256-62. doi: 10.3109/10428194.2013.803224. Epub 2013 Jun 14. Leuk Lymphoma. 2014. PMID: 23662993 Review.
References
-
- Jha S.K.; Pasrija D.; Sinha R.; Singh H.; Kumar V.; Sharan N.; Vidyarthi A.; Microbial L-Asparaginase: A review on current scenario and future prospects. IJPSR 2012,2012,3076-3090
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous